Associations between plasma ceramides and mortality in patients with coronary artery disease

Li, Qing; Wang, Xu; Pang, Juan; Yuan, Zuyi; Zhang, Hanyue; Xu, Zhongliang; Chen, Qian; Liu, Wenhua

doi:10.1016/j.atherosclerosis.2020.09.004

Cited by 29 publications

(33 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Circulating ceramide levels have also been suggested to predict the risk of cardiovascular events more accurately than traditional risk factors of LDL-cholesterol or HDL-cholesterol ( 44 , 58 ). The therapeutic potential and benefit of using circulating ceramides as predictors of CVD also appears to be consistent across ethnicity ( 40 , 52 , 57 , 59 ).…”

Section: Sphingolipids As Biomarkers Of Metabolic and Cardiovascular Diseasesmentioning

confidence: 99%

Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?

2021

View full text Add to dashboard Cite

Biomarkers are important tools for describing the adequacy or inadequacy of biological processes (to allow for the early and accurate diagnosis) and monitoring the biological effects of intervention strategies (to identify and develop optimal dose and treatment strategies). A number of lipid biomarkers are implicated in metabolic disease and the circulating levels of these biomarkers are used in clinical settings to predict and monitor disease severity. There is convincing evidence that specific circulating ceramide species can be used as biological predictors and markers of cardiovascular disease, atherosclerosis and type 2 diabetes mellitus. Here, we review the existing literature that investigated sphingolipids as biomarkers for metabolic disease prediction. What are the advantages and disadvantages? Are circulating ceramides predominantly produced in the liver? Will hepatic sphingolipid inhibitors be able to completely prevent and treat metabolic disease? As sphingolipids are being employed as biomarkers and potential metabolic disease treatments, we explore what is currently known and what still needs to be discovered.

show abstract

Section: Sphingolipids As Biomarkers Of Metabolic and Cardiovascular Diseasesmentioning

confidence: 99%

Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?

2021

View full text Add to dashboard Cite

show abstract

“…Our results are consistent with previous studies which demonstrated significant association between elevated ceramide levels and increased coronary atherosclerotic burden in STEMI patients 9,24 . Besides the proatherogenic role that ceramides may exert, studies have also documented that distinct ceramides are associated with specific plaque characteristics (plaque rupture, higher necrotic core fraction or higher lipid core burden) or increased cardiovascular and cerebrovascular risk [25][26][27] . However, our study was not designed to assess hard clinical endpoints and our findings should also be interpreted taking into consideration the singlecenter nature of the study and the restricted sample of participants.…”

Section: Discussionmentioning

confidence: 99%

Serum Ceramides as Prognostic Biomarkers of Large Thrombus Burden in Patients With STEMI: A Micro-Computed Tomography Study

Karagiannidis¹,

Papazoglou²,

Stalikas³

et al. 2021

Preprint

View full text Add to dashboard Cite

ST-elevation myocardial infarction (STEMI) remains one of the leading causes of morbidity and mortality worldwide. The identification of novel metabolic and imaging biomarkers could unveil key pathophysiological mechanisms at the molecular level and promote personalized care in patients with acute coronary syndromes. We studied 38 patients with STEMI who underwent primary percutaneous coronary intervention and thrombus aspiration. We sought to correlate serum ceramide levels with micro-CT quantified aspirated thrombus volume and relevant angiographic outcomes, including modified TIMI thrombus grade and pre- or post-procedural TIMI flow. Higher ceramide C16:0 levels were significantly, but weakly correlated with larger aspirated thrombus volume (Spearman r=0.326, p=0.046), larger intracoronary thrombus burden (Nagelkerke R2=0.236, p=0.030) and worse pre- and post-procedural TIMI flow (Nagelkerke R2=0.210; p=0.049 and Nagelkerke R2=0.277; p=0.039, respectively). Ceramides C24:0 and C24:1 were also significantly associated with larger intracoronary thrombus burden (Nagelkerke R2=0.311; p=0.008 and Nagelkerke R2=0.423; p=0.001, respectively). In conclusion, serum ceramide levels (mainly C16:0 and C24:1) were higher among patients with larger intracoronary and aspirated thrombus burden. This suggests that quantification of serum ceramides might improve risk-stratification of patients with STEMI and facilitate a more individualized approach in everyday clinical practice.

show abstract

“…Based on these results, the authors hypothesize that high ceramides levels promote the conversion of stable plaques into vulnerable plaque and plaque rupture. Li et al [25] studied 1704 patients with CAD from the large Guangdong Coronary Artery Disease Cohort and followed them for a median duration of 9.3 years. They measured plasma ceramide levels using ultra-high performance liquid chromatography-tandem mass spectrometry.…”

Section: Lipid-related Biomarkers Beyond Cholesterol and Triglyceridesmentioning

confidence: 99%

The year 2020 in Atherosclerosis

Binder¹,

Borén²,

Catapano³

et al. 2021

Atherosclerosis

View full text Add to dashboard Cite

Associations between plasma ceramides and mortality in patients with coronary artery disease

Cited by 29 publications

References 43 publications

Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?

Circulating Ceramides- Are Origins Important for Sphingolipid Biomarkers and Treatments?

Serum Ceramides as Prognostic Biomarkers of Large Thrombus Burden in Patients With STEMI: A Micro-Computed Tomography Study

The year 2020 in Atherosclerosis

Contact Info

Product

Resources

About